Overview

CHAMPION-AF Clinical Trial

Status:
Recruiting

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.

Phase:

N/A

Details

Lead Sponsor:

Boston Scientific Corporation

Treatments:

Anticoagulants